-
Thematic Analysis
Tech, Media and Telecom (TMT) Industry M&A Deals by Top Themes in 2022 – Thematic Intelligence
Tech, Media and Telecom Industry Mergers and Acquisitions Deals Report Overview The tech, media and telecom (TMT) sector witnessed 11,048 M&A deals worth $841 billion in 2022. North America lead the M&A activity in 2022. The top themes driving M&A activity in the TMT sector in 2022 were cloud and cybersecurity, while the internet & media sector was driven by internet advertising and digital media. The tech, media and telecom industry M&A deals thematic intelligence report provides an overview of...
-
Product Insights
Net Present Value Model: Firdapse
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Firdapse Drug Details Amifampridine (Firdapse) belongs...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – amifampridine phosphate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry amifampridine phosphate Drug Details Amifampridine (Firdapse) belongs to the class of central nervous system...
-
Product Insights
Myasthenia Gravis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery. The Myasthenia Gravis - Drugs In Development research report provides a comprehensive overview on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and...
-
Thematic Analysis
Space Tourism – An Analysis of Space Tourism’s Place in the Space Economy, Patents, Key Players, Space Hotels, Main Source Markets, Challenges and Opportunities
2021 marked a significant year for space tourism as new entrants announced their arrival. Within the same month, Richard Branson’s Virgin Galactic and Jeff Bezos’s Blue Origin successfully completed suborbital flights, with both billionaires being participants on these voyages to boost trust among potential customers. A few months later, Elon Musk’s SpaceX launched its all-civilian Inspiration4 mission. Its Dragon craft would orbit Earth for three days before splashing down in the ocean. 2021 was a memorable milestone for the sector as the...
-
Sector Analysis
Myasthenia Gravis – Epidemiology Forecast to 2028
Myasthenia gravis (MG) is the most common neuromuscular junction disorder, and is characterized by a fluctuating degree and variable combination of weakness in ocular, bulbar, limb, and respiratory muscles (Lai and Tseng, 2010). In this disease, receptors for acetylcholine at the neuromuscular junction are blocked, altered, or destroyed by the antibodies (immune proteins), which prevent the muscle from contracting. In some cases, antibodies to other proteins, such as the muscle-specific receptor tyrosine kinase (MuSK) protein, can also lead to impaired...
-
Track & Monitor
Tobacco Insights: October
“Tobacco Insights”, is a monthly report by Canadean which provides extensive and highly detailed information on the changing production and consumption patterns affected by the recent developments related to new laws and regulations globally.
-
Product Insights
Myasthenia Gravis Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Myasthenia Gravis Global Clinical Trials Review, H1, 2016" provides an overview of Myasthenia Gravis clinical trials scenario. This report provides top line data relating to the clinical trials on Myasthenia Gravis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Myasthenia Gravis – Opportunity Analysis and Forecasts to 2028
Myasthenia gravis (MG) is a rare chronic autoimmune and neuromuscular disorder. Most patients experience weakness of the muscles around the eye, which can cause drooping of the eyelids and blurred vision. In other types of MG, weakness can extend to other muscles and cause respiratory difficulties that require immediate attention to ensure the survival of the patient. Most cases of MG affect the eyes, and subtypes of MG are defined according to the severity of muscular weakness and patients’ response...